Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 1/20 | 0.59 |
| ▸ | RAB9A | P51151 | 1/20 | 0.59 |
| ▸ | HPGD | P15428 | 3/20 | 0.56 |
| ▸ | POLB | P06746 | 2/20 | 0.54 |
| ▸ | THRB | P10828 | 1/20 | 0.54 |
| ▸ | RECQL | P46063 | 1/20 | 0.54 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.54 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.54 |
| ▸ | PYGL | P06737 | 8/20 | 0.51 |
| ▸ | CTSL | P07711 | 1/20 | 0.50 |
| ▸ | SLC6A9 | P48067 | 1/20 | 0.48 |
| ▸ | LMNA | P02545 | 1/20 | 0.48 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.45 |
| ▸ | MAPT | P10636 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23430714 | 0.87 | HSD17B10 (0.49) | NPC1RAB9AHPGDPOLBTHRB | |
| SCHEMBL4148502 | 0.83 | POLB (0.76) | NPC1HPGDPOLBTHRBRECQL | |
| SCHEMBL6068233 | 0.83 | CES2 (0.55) | NPC1RAB9AL3MBTL1LMNAKDM4E | |
| SCHEMBL22231347 | 0.83 | ALDH1A1 (0.56) | NPC1RAB9AHPGDPOLBTHRB | |
| SCHEMBL12121109 | 0.81 | HPGD (0.68) | NPC1RAB9AHPGDPOLBTHRB | |
| SCHEMBL25376547 | 0.81 | SLC6A9 (0.46) | NPC1RAB9AL3MBTL1SLC6A9LMNA | |
| SCHEMBL3147754 | 0.81 | KDM4E (0.68) | NPC1RAB9AHPGDPYGLCTSL | |
| SCHEMBL883798 | 0.81 | HPGD (0.61) | NPC1RAB9AHPGDPYGLCTSL | |
| SCHEMBL12462051 | 0.81 | HPGD (0.57) | NPC1RAB9AHPGDPOLBTHRB | |
| SCHEMBL6356258 | 0.81 | PYGL (0.66) | NPC1RAB9AHPGDPOLBL3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210161869-A1 | ARYL DIHYDROPYRIDINONES AND PIPERIDINONE MGAT2 INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2021-06-03 | — | — | US | disclosed |
| WO-2012038081-A1 | SUBSTITUTED BENZAMIDE COMPOUNDS | Grünenthal GmbH (DE) | 2012-03-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210161869-A1 | ARYL DIHYDROPYRIDINONES AND PIPERIDINONE MGAT2 INHIBITORS | DGAT2, MGAT2, MGAT1 | NPC1 97/4885RAB9A 1973/4885HPGD 951/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.